The December US approval of Ferring’s cancer gene therapy Adstiladrin probably passed unnoticed by many biotech investors; it occurred during the Christmas lull, and the beneficiary was a private European company best known for reproductive health and the microbiome.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,